Mitotane

Contraindicated

Mitotane Doravirine Pifeltro Reduced doravirine exposure, reduced efficacy of doravirine and an increased risk of doravirine resistance Details Mitotane Fostemsavir Rukobia Reduced temsavir (the active moiety of fostemsavir) exposure and possible loss of virologic response Details Mitotane Lenacapavir Injection Sunlenca Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Mitotane Lenacapavir Oral Sunlenca Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Mitotane Lurasidone Latuda Reduced lurasidone exposure Details Mitotane Nifedipine Adalat® Reduced NIFEdipine exposure and reduced efficacy of NIFEdipine Details

Major

Mitotane Acetaminophen And Codeine Capital® & Codeine Explained Reduced codeine and morphine exposure, reduced opioid efficacy and precipitation of opioid withdrawal Details Mitotane Clindamycin ANTIROBE Explained Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI exposure Details Mitotane Buprenorphine Belbuca Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Mitotane Colchicine Colcrys Explained Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI exposure Details Mitotane Abemaciclib Verzenio Explained Decreased abemaciclib plasma concentration Details Mitotane Acalabrutinib Calquence Reduced acalabrutinib exposure Details Mitotane Alpelisib Piqray Reduced alpelisib exposure and reduced efficacy of alpelisib Details Mitotane Apixaban Eliquis Explained Reduced apixaban exposure Details Mitotane Apremilast Otezla Reduced apremilast exposure and an reduced efficacy of apremilast Details Mitotane Aripiprazole Injection Abilify Reduced ARIPiprazole exposure Details Mitotane Asciminib Scemblix Reduced asciminib exposure and reduced efficacy of asciminib Details Mitotane Atogepant Qulipta Reduced atogepant exposure Details Mitotane Avapritinib Ayvakit Reduced avapritinib exposure and reduced efficacy of avapritinib Details Mitotane Belumosudil Rezurock Explained Reduced belumosudil exposure and reduced efficacy of belumosudil Details Mitotane Cariprazine Vraylar Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Mitotane Abiraterone Abirtega Reduced abiraterone exposure and reduced efficacy of abiraterone Details Mitotane Aficamten Reduced aficamten exposure and reduced efficacy of aficamten Details Mitotane Amlodipine Amvaz® Reduced amLODIPine exposure Details Mitotane Axitinib Inlyta Reduced axitinib exposure Details Mitotane Bedaquiline Sirturo Reduced bedaquiline exposure and reduced efficacy of bedaquiline Details Mitotane Bortezomib Boruzu Reduced bortezomib exposure Details Mitotane Bosutinib Bosulif Reduced bosutinib exposure and reduced efficacy of bosutinib Details Mitotane Brexpiprazole Rexulti Reduced brexpiprazole exposure Details Mitotane Brigatinib Alunbrig Reduced brigatinib efficacy Details Mitotane Cabozantinib Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Mitotane Cabozantinib (Thyroid Cancer) Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Mitotane Capmatinib Tabrecta Decreased capmatinib exposure and reduction of antitumor activity Details Mitotane Clindamycin Injection ANTIROBE Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI exposure Details Mitotane Clindamycin Topical C/T/S® Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI exposure Details Mitotane Clindamycin Vaginal Cleocin Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI exposure Details Mitotane Cobimetinib Cotellic Decreased cobimetinib plasma concentrations Details Mitotane Cyclosporine Injection Atopica Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI exposure Details Mitotane Cyclosporine Ophthalmic Cequa Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI exposure Details Mitotane Dasatinib Phyrago Reduced dasatinib exposure and reduced efficacy of dasatinib Details